熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
瑞典Affibody
Affibody是一家瑞典生物技術(shù)公司,專注于在其獨(dú)有的專利技術(shù)平臺(tái)基礎(chǔ)上開(kāi)發(fā)新一代生物藥品, 這些平臺(tái)是Affibody?分子和AlbumodTM。
Affibody正在開(kāi)發(fā)一系列創(chuàng)新藥物課題,此外也提供半衰期延長(zhǎng)技術(shù)AlbumodTM,用于對(duì)外授權(quán)。Affibody與若干公司有持續(xù)的商業(yè)關(guān)系,包括Algeta、Amylin、Swedish Orphan Biovitrum、GE和Thermo Fisher。
Affibody由瑞典皇家理工學(xué)院和卡羅琳斯卡研究所的研究人員于1998年創(chuàng)立,總部在瑞典斯德哥爾摩。公司大股東包括HealthCap和Investor Growth Capital。
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody? molecules and Albumod?.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod?, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.